Condition: Hidradenitis Suppurativa · Sponsor: Incyte Corporation
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Investigative Site US020 | Phoenix, Arizona, United States | — |
| Investigative Site US033 | Scottsdale, Arizona, United States | — |
| Investigative Site US054 | Tempe, Arizona, United States | — |
| Investigative Site US002 | Fayetteville, Arkansas, United States | — |
| Investigative Site US055 | Brea, California, United States | — |
| Investigative Site US004 | Laguna Niguel, California, United States | — |
| Investigative Site US007 | Los Angeles, California, United States | — |
| Investigative Site US013 | San Diego, California, United States | — |
| Investigative Site US060 | San Diego, California, United States | — |
| Investigative Site US038 | San Diego, California, United States | — |
| Investigative Site US059 | Aurora, Colorado, United States | — |
| Investigative Site US045 | Boynton Beach, Florida, United States | — |
+ 89 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06959225